New treatments for acute humoral rejection of kidney allografts

Bibliography

• HALLORAN PF, WADGYMAR A, RITCHIE S et al.: The significance of anti-class I antibody response. I. Clinical and pathologic features of anti-class I mediated rejection. Transplantation (1990) 49:85-91.
   PubMed Web of Science ®Google Scholar
• HALLORAN PF, SCHLAUT J, SOLEZ K, SRINIVASA NS: The significance of anti-class I antibody response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation (1992) 53:550-555.
   PubMed Web of Science ®Google Scholar
• TRPKOV K, CAMPBELL T, PAZDERKA F et al.: Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Transplantation (1996) 61:1586-1592.
   PubMed Web of Science ®Google Scholar
• FEUCHT HE, FELBER E, GOKEL MJ et al.: Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin. Exp. Immunol. (1991) 86:464-470.
   PubMed Web of Science ®Google Scholar
• FEUCHT HE, SCHNEEBERGER H, HILLEBRAND et al.: Capillary deposition of C4d complement fragment and early graft loss. Kidney Int. (1993) 43:1333-1338.
   PubMed Web of Science ®Google Scholar
• PASCUAL M, SAIDMAN S, TOLKOFF-RUBIN N et al.: Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation (1998) 66:1460-1464.
   PubMed Web of Science ®Google Scholar
• COLLINS AB, SCHNEEBERGER EE, PASCUAL M et al.: Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol. (1999) 10:2208-2214.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY RA, HARDY MA, JORDAN SC et al.: Antibody Working Group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation (2004) 78:181-185.
   PubMed Web of Science ®Google Scholar
• CRESPO M, PASCUAL M, TOLKOFF-RUBIN N et al.: Acute humoral rejection in renal allograft recipients: Incidence, serology and clinical characteristics. Transplantation (2001) 71:652-658.
   PubMed Web of Science ®Google Scholar
• MAUIYYEDI S, CRESPO M, COLLINS AB et al.: Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology and pathologic classification. J. Am. Soc. Nephrol. (2002) 13:779-787.
   PubMed Web of Science ®Google Scholar
• BOHMIG GA, EXNER M, HABICHT A et al.: Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J. Am. Soc. Nephrol. (2002) 13:1091-1099.
   PubMed Web of Science ®Google Scholar
• MOLL S, PASCUAL M: Humoral rejection of organ allografts. Am. J. Transplant. (2005) 5:2611-2618.
   PubMed Web of Science ®Google Scholar
• HERZENBERG AM, GILL JS, DJURDJEV O, MAGIL AB: C4d deposition in acute rejection: an independent long-term prognostic factor. J. Am. Soc. Nephrol. (2002) 13:234-241.
   PubMed Web of Science ®Google Scholar
• KARPINSKI M, RUSH D, JEFFERY J et al.: Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J. Am. Soc. Nephrol. (2001) 12:2807-2814.
   PubMed Web of Science ®Google Scholar
• PERREY C, BRENCHLEY PE, JOHNSON RW, MARTIN S: An association between antibodies specific for endothelial cells and renal transplant failure. Transpl. Immunol. (1998) 6:101-106.
   PubMed Web of Science ®Google Scholar
• SUMITRAN-HOLGERSSON S, WILCZEK HE, HOLGERSSON J, SODERSTROM K: Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation (2002) 74:268-277.
   PubMed Web of Science ®Google Scholar
• BALDWIN WM, HALLORAN PF: Clinical syndromes associated with antibody in allografts. In: Kidney Transplant Rejection. Racusen LC, Solez K, Burdick JF (Eds), Marcel Decker, New York, USA (1998) 3:127-147.
   Google Scholar
• HILL P, GAGLIARDINI E, RUGGENENTI P et al.: Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with campath-1H induction therapy. Nephrol. Dial. Transplant. (2005) 20:1741-1744.
   PubMed Web of Science ®Google Scholar
• WEINSTEIN D, BRAUN WE, COOK D et al.: Ultra-late antibody-mediated rejection 30 years after a living-related renal allograft. Am. J. Transplant. (2005) 5:2576-2581.
   PubMed Web of Science ®Google Scholar
• BAID S, TOLKOFF-RUBIN N, SAIDMAN S et al.: Acute humoral rejection in hepatitis c-infected renal transplant recipients receiving antiviral therapy. Am. J. Transplant. (2003) 3:74-78.
   PubMed Web of Science ®Google Scholar
• TAKAHASHASHI K, SAITO K, TAKAHARA S et al.; JAPANESE ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION COMMITTEE: Excellent long-term outcome of ABO incompatible living donor kidney transplantation in Japan. Am. J. Transplant. (2004) 4:1089-1096.
   PubMed Web of Science ®Google Scholar
• WARREN DS, ZACHARY AA, SONNENDAY CJ et al.: Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am. J. Transplant. (2004) 4:561-568.
   PubMed Web of Science ®Google Scholar
• TYDEN G, KUMLIENJ G, GENBERG H et al.: ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am. J. Transplant. (2005) 5:145-148.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY RA, ZACHARY AA: Transplanting patients with a positive donor-specific crossmatch: a single center’s perspective. Pediatr. Transplant. (2004) 8:535-542.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY RA, ZACHARY AA, RACUSEN LC et al.: Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match positive recipients. Transplantation (2000) 70:887-895.
   PubMed Web of Science ®Google Scholar
• JORDAN SC, QUARTEL AW, CZER LSC et al.: Postransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation (1988) 66:800-805.
   Google Scholar
• ROCHA PN, BUTTERLY DW, GREENBERG A et al.: Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation (2003) 75:1490-1495.
   PubMed Web of Science ®Google Scholar
• WHITE NB, GREENSTEIN SM, CANTAFIO AW et al.: Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation (2004) 78:772-774.
   PubMed Web of Science ®Google Scholar
• BOHMIG GA, REGELE H, EXNER M et al.: C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J. Am. Soc. Nephrol. (2001) 12:2482-2489.
   PubMed Web of Science ®Google Scholar
• IBERNON M, GIL-VERNET S, CARRERA M et al.: Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant. Proc. (2005) 37:3743-3745.
   PubMed Web of Science ®Google Scholar
• BECKER YT, BECKER BN, PIRSCH JD et al.: Rituximab as treatment for refractory kidney transplant rejection. Am. J. Transplant. (2004) 4:996-1001.
   PubMed Web of Science ®Google Scholar
• LEHRICH RW, ROCHA PN, REINSMOEN N et al.: Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. Hum. Immunol. (2005) 66:350-358.
   PubMed Web of Science ®Google Scholar
• ABRAHAM KA, BROWN C, CONLON PJ et al.: Plasmapheresis as rescue therapy in accelerated acute humoral rejection. J. Clin. Apheresis (2003) 18:103-110.
   PubMed Web of Science ®Google Scholar
• CASADEI DH, RIAL MC, RAIMONDI E et al.: Complementary data about the inhibitory effects of intravenous immunoglobulins in vitro and in vivo. Transplantation (1997) 63:1191-1192.
   PubMed Web of Science ®Google Scholar
• JORDAN SC, TYAN D, STABLEIN D et al.: Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J. Am. Soc. Nephrol. (2004) 15:3256-3262.
   PubMed Web of Science ®Google Scholar
• SIVASAI KS, MOHANAKUMAR T, PHELAN D et al.: Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates. Clin. Exp. Immunol. (2000) 119:559-565.
   PubMed Web of Science ®Google Scholar
• STEGALL MD, GLOOR J, WINTERS JM et al.: A comparison of plasmapheresis versus high dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am. J. Transplant. (2006) 6:346-351.
   PubMed Web of Science ®Google Scholar
• SMITH KG, ISBEL NM, CATTON MG et al.: Suppression of the humoral immune response by mycophenolate mofetil. Nephrol. Dial. Transplant. (1998) 13:160-164.
   PubMed Web of Science ®Google Scholar
• BROEDERS N, WISSING KM, CRUSIAUX A et al.: Mycophenolate mofetil, together with cyclosporine A, prevents anti-OKT3 antibody response in kidney transplant recipients. J. Am. Soc. Nephrol. (1998) 9:1521-1525.
   PubMed Web of Science ®Google Scholar
• TERASAKI PI, OZAWA M: Predicting kidney graft failure by HLA antibodies: a prospective trial. Am. J. Transplant. (2004) 4:438-443.
   PubMed Web of Science ®Google Scholar
• VIEIRA CA, AGARWAL A, BOOK BK et al.: Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation (2004) 77:542-548.
   PubMed Web of Science ®Google Scholar
• TYDEN G, KUMLIEN G, FEHRMAN I: Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation (2003) 76:730-731.
   PubMed Web of Science ®Google Scholar
• GLOOR JM, DEGOEY SR, PINEDA AA et al.: Overcoming a positive crossmatch in living-donor kidney transplantation. Am. J. Transplant. (2003) 3:1017-1023.
   PubMed Web of Science ®Google Scholar
• ARANDA JM Jr, SCORNIK JC, NORMANN SJ et al.: Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation (2002) 73:907-910.
   PubMed Web of Science ®Google Scholar
• GARRETT HE, GROSHART K, DUVAL-SEARMAN D et al.: Treatment of acute humoral rejection with rituximab. Ann. Thorac. Surg. (2002) 74:1240-1242.
   PubMed Web of Science ®Google Scholar
• CRESPO M, AROSTEGUI JJ, ESFORZADO N et al.: A liver graft does not always protect a kidney graft from acute humoral rejection in combined transplantation. Transplant. Int. (2005) 18(Suppl. 1):44.
   Google Scholar
• GENBERG H, HANSSON A, WERNERSON A, WENNBERG L, TYDEN G: Pharmacodynamics of rituximab in kidney allotransplantation. Am. J. Transplant. (2006) 6:2418-2428.
   PubMed Web of Science ®Google Scholar
• BEARDEN CM, AGARWAL A, BOOK BK et al.: Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am. J. Transplant. (2005) 5:50-57.
   PubMed Web of Science ®Google Scholar
• TOKUNAGA M, FUJII K, SAITO K et al.: Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (2005) 44:176-182.
   PubMed Web of Science ®Google Scholar
• JORDAN ML, NARAGHI R, SHAPIRO R et al.: Tacrolimus rescue therapy for renal allograft rejection – five-year experience. Transplantation (1997) 63:223-228.
   PubMed Web of Science ®Google Scholar
• LOSS GE Jr, GREWAL HP, SIEGEL CT et al.: Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. Transplant. Proc. (1998) 30:1249-1250.
   PubMed Web of Science ®Google Scholar
• JURCEVIC S, DUNN MJ, CRISP S et al.: A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. Transplantation (1998) 65:1197-1202.
   PubMed Web of Science ®Google Scholar
• THERUVATH TP, SAIDMAN SL, MAUIYYEDI S et al.: Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation (2001) 72:77-83.
   PubMed Web of Science ®Google Scholar
• VINCENTI F: Protein therapies and antiproliferatives: a new paradigm in immunosuppression. Transplant. Rev. (2005) 19:179-185.
   Google Scholar
• BENIAMINOVITZ A, ITESCU S, LIETZ K et al.: Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N. Engl. J. Med. (2000) 342:613-619.
   PubMed Web of Science ®Google Scholar
• KNECHTLE SJ, PIRSCH JD, FECHNER J Jr et al.: Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am. J. Transplant. (2003) 3:722-730.
   PubMed Web of Science ®Google Scholar
• SUNDERS RN, MATCALFE MS, NICHOLSAN ML: Rapamycin in transplantation: a review of the evidence. Kidney Int. (2001) 59:3-16.
   PubMed Web of Science ®Google Scholar
• AAGAARD-TILLERY KM, JELINEK DF: Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol. (1994) 156:493-507.
   PubMed Web of Science ®Google Scholar
• PESCOVITZ MD, BOOK BK, HENSON S et al.: The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin. Am. J. Transplant. (2003) 3:497-500.
   PubMed Web of Science ®Google Scholar
• PASCUAL M, DUCHOSAL MA, STEIGER G et al.: Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes. J. Immunol. (1993) 151:1702-1711.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN JL, DELLINGER RP, STRAUBE RC et al.: Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit. Care Med. (2000) 28:3149-3154.
   PubMed Web of Science ®Google Scholar
• PIERSON RN III, LOYD JE, GOODWIN A et al.: Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. Transplantation (2002) 74:79-84.
   PubMed Web of Science ®Google Scholar
• HILLMEN P, YOUNG NS, SCHUBERT J et al.: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. (2006) 355:1233-1243.
   PubMed Web of Science ®Google Scholar
• GOLDENBERG DM: Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev. Anticancer Ther. (2006) 6:1341-1353.
   PubMed Web of Science ®Google Scholar
• KEYSTONE E: B cell targeted therapies. Arthritis Res. Ther. (2005) 7(Suppl. 3):S13-S18.
   PubMedGoogle Scholar